CSL, one of the largest healthcare companies on the ASX, is in a difficult spot right now. The company has long been known for plasma‑derived therapies and flu vaccines and in 2022 it added kidney‑focused specialist Vifor Pharma for about US$12 billion. A recent earnings miss combined with the sudden exit of its chief executive after less than three years in the role and the earlier loss of its chief financial officer has shaken confidence. Despite this the board is signalling stability by keeping full‑year earnings guidance intact and appointing a seasoned internal leader as interim chief while it searches for a permanent replacement.
Under the surface the numbers show why the mood has shifted. Total revenue eased 1.8% to around US$8.3 billion while reported net profit plunged 86% to roughly US$286 million after more than US$1 billion in post‑tax impairments tied to shelved mRNA vaccine technology, reduced expectations for an iron therapy under pressure from generics and redundant facilities. Stripping out these charges, underlying profit fell a more modest 7% to about US$1.95 billion. Management is rolling out a transformation program targeting US$550 million in annual cost savings by 2027‑28, funded by US$700‑770 million in restructuring and efficiency spending and cutting around 3,000 roles. Early on they expect about US$100 million in savings this year and say around two‑thirds of the restructuring costs are already booked.
The operating picture varies sharply across divisions. The core plasma business saw revenue drop 7% to roughly US$5.45 billion and earnings slide 9% to about US$2.33 billion, hit by lower immunoglobulin sales of around US$3 billion, US Medicare drug pricing reforms that shaved about US$100 million off revenue and policy‑driven weakness in Chinese demand for albumin. Some products, like gene therapy for haemophilia, are growing but others face cheaper competition and will likely take years to recover. By contrast the flu vaccine arm limited revenue decline to about 2% at roughly US$1.65 billion despite softer US demand and Vifor’s kidney‑focused portfolio lifted its top line slightly to about US$1.22 billion while growing operating profit by 22% to around US$636 million. Research and development spending has been trimmed about 7% to US$600 million yet the company is still cutting overlaps between legacy CSL Behring and Vifor and redirecting funds into key markets like the US and China.
Stepping back, CSL still looks like a cash‑generating heavyweight that is temporarily out of favour rather than structurally broken but the path forward is not guaranteed. Operating cash flow sits at about US$1.3 billion, the board has expanded the share buyback from US$500 million to US$750 million after repurchasing roughly US$400 million in the first half and the interim dividend remains steady at US$1.30 per share even as the stock has slid from pandemic‑era peaks near $319 to around the mid‑$140s. Management is banking on modest revenue growth of 2‑3% and a 4‑7% lift in underlying earnings this year, helped by new therapies for conditions like hereditary angioedema, a potential rebound in Chinese albumin demand and fresh licensing income such as a US$100 million upfront payment for an inflammatory antibody deal. Longer term the company seems to be betting that disciplined cost cuts, a refreshed product pipeline and steady plasma collection improvements will eventually win back investors who currently see more risk than reward.
